Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a
registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type
2 diabetes who are currently taking oral medications and have not previously taken insulin.
Change in HbA1c levels will be reviewed to determine superiority or inferiority of the AIR
Inhaled Insulin regimen.